|
시장보고서
상품코드
2078778
방사선 유발 구강 점막염 치료 시장 규모, 점유율 및 성장 분석 : 치료법별, 중증도별, 유통경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Radiotherapy Induced Oral Mucositis Treatment Market Size, Share, and Growth Analysis, By Treatment (Palifermin (Kepivance), Mouthwashes & Rinses), By Severity, By Distribution, By End-User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 방사선 유발 구강 점막염 치료 시장 규모는 2024년에 6억 8,250만 달러로 평가되었고, 2025년 7억 3,184만 달러에서 2033년까지 12억 8,540만 달러로 성장하여 예측 기간(2026-2033년)에 CAGR 7.23%를 기록할 전망입니다.
방사선 유발 구강 점막염 치료 세계 시장은 의료 시스템에 보조 치료 프로토콜이 도입된 것을 원동력으로 삼아 눈부신 성장을 이루고 있습니다. 구강 내 미생물 군집의 특성과 유전자 프로파일에 맞추어 방사선 조사량을 조정하는 위험도 계층화 프로토콜을 통해, 점막염의 발병률과 회복 기간이 효과적으로 단축되었습니다. 이러한 성공에 힘입어 병원에 대한 보상률이 상승했으며, 민간 및 공적 보험사 모두의 보상 기준이 확대되고 있습니다. 주목할 만한 진전으로, 유럽의 종양학 네트워크가 저출력 레이저 요법과 벤지다민을 병용하여 도입한 사례가 있는데, 이를 통해 중증 구강 점막염 사례가 35% 감소했으며, 보험 환급액도 대폭 증가했습니다. 이러한 성과를 바탕으로 각 제약사는 대규모 임상시험에 대한 투자와 차세대 제제 개발에 주력하고 있으며, 특히 소아 종양학 등 그동안 충분한 의료 서비스가 제공되지 않았던 시장을 중점적으로 공략하고 있습니다. 이를 통해 환자의 접근성이 향상되고, 지지 요법 분야의 지속적인 혁신이 촉진될 것으로 기대됩니다.
세계 방사선 유발 구강 점막염 치료 시장의 성장 요인
방사선 치료 중 발생하는 구강 점막염이 환자의 삶의 질에 미치는 중대한 영향에 대한 임상 의사들의 인식이 높아지면서, 표적 치료법에 대한 수요가 증가하고 있습니다. 이러한 인식을 바탕으로, 통증을 완화하고 감염 위험을 줄이며 암 치료를 원활하게 진행하는 것을 목적으로 한 적극적인 관리 방식이 도입되고 있습니다. 의료 서비스 제공업체들이 구강 건강 유지를 중시하는 다직종 연계 케어 모델을 도입함에 따라, 점막 염증을 관리하기 위한 근거 기반 해결책에 대한 관심이 높아지고 있으며, 이것이 시장 성장을 견인하고 있습니다. 또한, 의학 교육 및 임상 지침의 개정을 계기로 예방 및 치료 전략에 대한 관심이 지속되고 있어, 혁신적인 점막염 치료제의 수용이 확대되고 있습니다.
세계 방사선 유발 구강 점막염 치료 시장의 제약 요인
구강 점막염에 대한 첨단 치료법은 비용이 매우 높기 때문에 특히 재정적 제약이 치료 결정에 큰 영향을 미치는 의료 환경에서 치료 접근의 장벽이 되고 있습니다. 병원이나 종양 치료 시설에서는 혁신적인 치료법의 장점과 비용을 저울질하는 경우가 빈번하며, 그 결과 많은 시설이 고가의 독자 개발 치료법 대신 더 저렴한 제네릭 의약품이나 지지 요법을 선택하고 있습니다. 이러한 경제적 과제는 이러한 첨단 치료법의 광범위한 수용을 저해하고, 임상 현장에의 도입을 지연시키며, 궁극적으로는 전 세계의 다양한 환자 집단이 치료에 접근하는 것을 방해하고 있습니다. 그 결과, 가격상의 제약과 보험 급여 관련 문제가 효과적인 점막염 치료법의 이용 확대에 있어 큰 걸림돌이 되고 있습니다.
세계 방사선 유발 구강 점막염 치료 시장 동향
세계 방사선 유발 구강 점막염 치료 시장에서는 다양한 전문직으로 구성된 종양학 팀 간의 협력을 촉진하는 통합 치료 경로로 뚜렷한 전환이 나타나고 있습니다. 방사선종양 전문의, 치과 전문의, 영양사, 간호진이 협력하는 이 접근법은 표준화된 평가 도구와 조기 개입 전략을 중시하며, 구강 점막염의 중증도를 크게 완화하는 데 기여하고 있습니다. 실시간 데이터 공유와 근거에 기반한 치료 계획 조정이 치료 프로토콜의 필수 요소로 자리 잡은 가운데, 이러한 협력 모델은 환자 중심의 치료를 강화하고, 암 치료 순응도를 높이며, 궁극적으로 전 세계적으로 치료 성과 전반을 향상시키고 있습니다. 이러한 추세는 다양한 임상 현장에서 점막 합병증을 줄이면서 환자의 회복을 최적화하려는 노력을 반영하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 방사선 유발 구강 점막염 치료 시장 규모 : 치료별
세계의 방사선 유발 구강 점막염 치료 시장 규모 : 중증도별
세계의 방사선 유발 구강 점막염 치료 시장 규모 : 유통별
세계의 방사선 유발 구강 점막염 치료 시장 규모 : 최종사용자별
세계의 방사선 유발 구강 점막염 치료 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSHGlobal Radiotherapy Induced Oral Mucositis Treatment Market size was valued at USD 682.5 Million in 2024 and is poised to grow from USD 731.84 Million in 2025 to USD 1285.4 Million by 2033, growing at a CAGR of 7.23% during the forecast period (2026-2033).
The global market for radiotherapy-induced oral mucositis treatment is experiencing significant growth, fueled by the integration of supportive care pathways into healthcare systems. Risk-stratified protocols aligning radiation doses with oral microbiome characteristics and genetic profiles have effectively reduced mucositis incidence and recovery times. This success is driving higher hospital reimbursement rates, expanding both private and public payor formulas. A notable development involved a European oncology network incorporating low-level laser therapy and Benzydamine, yielding a 35% reduction in severe mucositis cases and significant reimbursement gains. These outcomes have spurred manufacturers to invest in large-scale trials and develop next-generation formulations, particularly targeting underserved markets, such as pediatric oncology, which is poised to enhance patient access and stimulate ongoing innovation in supportive care.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Radiotherapy Induced Oral Mucositis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Radiotherapy Induced Oral Mucositis Treatment Market Segments Analysis
Global radiotherapy induced oral mucositis treatment market is segmented by treatment, severity, distribution, end-user and region. Based on treatment, the market is segmented into Palifermin (Kepivance), Mouthwashes & Rinses, Low-Level Laser Therapy (LLLT) and Cryotherapy. Based on severity, the market is segmented into Grade 1-2 (Mild-Moderate) and Grade 3-4 (Severe). Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Radiation Oncology Centers and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Radiotherapy Induced Oral Mucositis Treatment Market
The growing acknowledgment among clinicians regarding the significant impact of oral mucositis on patient quality of life during radiotherapy is fueling the demand for targeted treatment options. This awareness has led to the implementation of proactive management approaches aimed at alleviating pain, lowering infection risks, and ensuring seamless cancer treatment. As healthcare providers adopt multidisciplinary care models that emphasize supportive oral health practices, there is an increased interest in evidence-based solutions to manage mucosal inflammation, driving market growth. Furthermore, the ongoing focus on preventive and therapeutic strategies, bolstered by medical education and updates in clinical guidelines, is enhancing the acceptance of innovative mucositis therapeutics.
Restraints in the Global Radiotherapy Induced Oral Mucositis Treatment Market
The high cost of advanced therapies for oral mucositis creates barriers to access, especially in low-resource healthcare environments where financial limitations heavily influence purchasing decisions. Hospitals and oncology facilities frequently find themselves weighing the benefits of innovative treatments against their costs, leading many to choose more affordable generic alternatives or supportive care options rather than costly proprietary solutions. This economic challenge hampers the widespread acceptance and slows the integration of these advanced therapies into clinical practice, ultimately impeding their availability to diverse patient populations globally. Consequently, pricing constraints and issues with reimbursement serve as significant hurdles to expanding the use of effective mucositis treatments.
Market Trends of the Global Radiotherapy Induced Oral Mucositis Treatment Market
The Global Radiotherapy Induced Oral Mucositis Treatment market is witnessing a notable shift towards integrated care pathways that promote collaboration among multidisciplinary oncology teams. This approach, which aligns radiation oncologists, dental specialists, nutritionists, and nursing staff, emphasizes standardized assessment tools and early intervention strategies, leading to a significant reduction in the severity of oral mucositis. As real-time data sharing and evidence-based adjustments become integral to treatment protocols, these collaborative models enhance patient-centric care, improve adherence to cancer therapies, and ultimately strengthen overall treatment outcomes globally. The trend reflects a commitment to optimizing patient recovery while mitigating mucosal complications in various clinical settings.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Radiotherapy Induced Oral Mucositis Treatment Market Size by Treatment & CAGR (2026-2033)
- Market Overview
- Palifermin (Kepivance)
- Mouthwashes & Rinses
- Low-Level Laser Therapy (LLLT)
- Cryotherapy
Global Radiotherapy Induced Oral Mucositis Treatment Market Size by Severity & CAGR (2026-2033)
- Market Overview
- Grade 1-2 (Mild-Moderate)
- Grade 3-4 (Severe)
Global Radiotherapy Induced Oral Mucositis Treatment Market Size by Distribution & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
Global Radiotherapy Induced Oral Mucositis Treatment Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Radiation Oncology Centers
- Hospitals
Global Radiotherapy Induced Oral Mucositis Treatment Market Size & CAGR (2026-2033)
- North America (Treatment, Severity, Distribution, End-User)
- US
- Canada
- Europe (Treatment, Severity, Distribution, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment, Severity, Distribution, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment, Severity, Distribution, End-User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment, Severity, Distribution, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Swedish Orphan Biovitrum (Kepivance)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bioxcel Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Enzymatic Therapy
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aeterna Zentaris
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocon Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Integra LifeSciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Colgate-Palmolive (Oral Care)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GUM (Sunstar Group)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- 3M ESPE (Solventum)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioAlliance Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MedPharm Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aminogen (Aminogen.com)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Salix Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Evofem Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Akeso Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nuo Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
